In addition to ovarian serous carcinomas, more than 4% of esophageal carcinoma, skin cutaneous melanoma, uterine corpus endometrial carcinoma, diffuse large B-cell lymphoma, and bladder urothelial carcinoma obtained TFAP2A gene alteration (Figure 3A). Here, TFAP2A is linked to ovarian serous carcinoma.